Vyome Holdings, Inc. (HIND) Stock Score, Valuation & Financial Research
Vyome Holdings, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 18/100.
Quick answer for HIND
Vyome Holdings, Inc. currently has a Wall Street Score of 18/100. The stored market price is $1.95. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -2.9 points. These figures are a research snapshot, not a buy or sell recommendation.
What Vyome Holdings, Inc. does
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
HIND financial snapshot
- Wall Street Score:
- 18/100
- Current price:
- $1.95
- Market capitalization:
- $13.7M
- Revenue:
- $130K
- Net income:
- $-11.3M
- Free cash flow:
- $-3.7M
- Cash:
- $7.9M
- Total debt:
- $17K
- EPS:
- -1.61
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.6%.
- Free cash flow is $-3.7M, showing cash burn in the current stored period.
- The balance sheet shows $7.9M of cash versus $17K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -2.9 points: HIND decreased 2.9 points because Revenue declined by 21 points, Asset declined by 7.6 points, Buffett declined by 5.3 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HIND
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.